Search

Iovance Biotherapeutics Inc

Gesloten

SectorGezondheidszorg

3.87 -2.27

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.91

Max

4.04

Belangrijke statistieken

By Trading Economics

Inkomsten

-7.1M

-79M

Verkoop

-15M

71M

EPS

-0.19

Winstmarge

-110.661

Werknemers

975

EBITDA

-3.4M

-71M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+142.57% upside

Dividenden

By Acuity

Volgende Winsten

6 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

170M

1.9B

Vorige openingsprijs

6.14

Vorige sluitingsprijs

3.87

Nieuwssentiment

By Acuity

25%

75%

68 / 342 Rangschikking in Healthcare

Iovance Biotherapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 jul 2026, 23:46 UTC

News

PayPal Holdings Inc. shares are lower in after-market trading despite expanding buy now, pay later options in the UK with a new Pay in 30 Days feature.

14 jul 2026, 23:41 UTC

Event
News

Biogen Inc shares are higher in after-market trading following positive Phase 2 CELIA study results for diranersen, which targets tau in early Alzheimer's disease.

14 jul 2026, 23:32 UTC

Social Media
News

Advanced Micro Devices shares rose in after-market hours following price target increases by analysts, including KeyBanc's $725 target amid strong demand for EPYC processors.

14 jul 2026, 23:32 UTC

News
Social Media

Micron Technology's stock rose in after-market trading following a lower-than-expected inflation report and positive sentiment from IBM regarding memory chip demand.

14 jul 2026, 23:31 UTC

News
Social Media

Amazon.com Inc shares are higher in after-market trading amid positive sentiment. Analysts maintain a bullish outlook on the company's long-term investment strategy.

14 jul 2026, 23:31 UTC

News

Netflix shares are higher in after-hours trading, buoyed by investor confidence despite rising subscription costs and regulatory scrutiny amid broader positive market sentiment.

14 jul 2026, 23:31 UTC

News
Social Media

Alphabet Inc signed a fixed-price power purchase agreement for its largest solar-plus-storage project in the U.S. Shares are lower in after-market hours.

14 jul 2026, 23:31 UTC

News
Correlated Moves

Apple Inc. shares were little changed after KeyBanc downgraded the rating to Sell with a price target of $250. OpenAI countered Apple's trade secret lawsuit claims.

14 jul 2026, 23:11 UTC

News

The Australian Dollar is trading higher against the Singapore Dollar, supported by rising crude oil prices and improved U.S. inflation data.

14 jul 2026, 23:06 UTC

News

Fiserv Inc. will release its second-quarter earnings on August 6, 2026, with shares trading higher in after-market hours amid positive sentiment.

14 jul 2026, 23:06 UTC

News

Workday Inc. shares declined slightly in after-market trading following a challenging year, despite reporting 14.7% year-over-year growth in subscription revenue.

14 jul 2026, 23:06 UTC

Macro News
News
Correlated Moves
ETF Constituents

Health Care Select Sector SPDR Fund is trading higher after proposed Medicare reforms by CMS and Anthem's new Alzheimer's testing coverage announcement.

14 jul 2026, 23:06 UTC

News

United States Oil Fund LP trades higher in after-market hours as Iran withdraws from its agreement with the U.S., raising oil supply stability concerns.

14 jul 2026, 23:01 UTC

News

Cintas Corp is higher in after-market trading, with its market capitalization surpassing Target Corp, positioning it 193rd in the S&P 500.

14 jul 2026, 22:32 UTC

Correlated Moves
News

Geopolitical tensions and rising crude oil prices have contributed to an increase in CHF/HKD since Monday's close, reflecting broader market sentiment.

14 jul 2026, 20:52 UTC

Correlated Moves
News

Vanguard Total Bond Market ETF advances in after-hours trading following a significant drop in the U.S. Consumer Price Index, easing inflation concerns and boosting Treasury demand.

14 jul 2026, 20:07 UTC

News
Social Media

eBay shares are lower amid mixed analyst ratings and social media concerns about growth metrics. Jefferies raised the price target to $75 while maintaining an Underperform rating.

14 jul 2026, 20:07 UTC

News

Xcel Energy shares are lower amid a settlement proposal for a $123 million revenue increase, with regulatory hearings scheduled for July 2026.

14 jul 2026, 20:07 UTC

Social Media
Correlated Moves
News
Macro Event

Gold prices rose sharply today, with August futures reaching $4,092 an ounce after cooler CPI data. SPDR Gold Shares also benefited from this upward trend.

14 jul 2026, 20:07 UTC

News
Social Media

Electronic Arts is set to launch EA Sports Madden NFL 27 Arcade Edition on August 6, contributing to positive investor sentiment as shares trade higher.

14 jul 2026, 20:02 UTC

News
Macro Event

American Airlines shares are lower amid mixed options sentiment and elevated trading volume. The stock is set to report earnings on July 23.

14 jul 2026, 20:02 UTC

Correlated Moves
News

Intuitive Surgical shares are lower as Baird cuts price target to $525 from $610. The stock has reached a 25-month low at $395.02.

14 jul 2026, 20:02 UTC

News
Macro Event

Take-Two Interactive shares are trading lower amid recent inflation data, despite earlier gains during the session reflecting broader market pressures in the gaming sector.

14 jul 2026, 19:56 UTC

News

Citigroup maintained its Buy rating on Monster Beverage and raised the price target to $113, contributing to a higher stock price since Monday's close.

14 jul 2026, 19:52 UTC

Correlated Moves
ETF Constituents
News

Fitch affirmed Canada's credit rating at AA+, boosting sentiment for Canadian assets. The iShares MSCI Canada ETF is trading higher, supported by favorable USD/CAD movement.

14 jul 2026, 19:52 UTC

Macro Event
News

NTAL launched to amplify daily participation in NTAP amid strong activity.

14 jul 2026, 19:46 UTC

News

Marriott International shares rise amid positive sentiment from a new collaboration between The Ritz-Carlton and MERIT Beauty, with Macquarie raising its price target to $365.

14 jul 2026, 19:45 UTC

News
Correlated Moves

Intuit Inc. shares are lower amid a class action lawsuit alleging securities fraud and an investigation into potential violations of federal securities laws.

14 jul 2026, 19:41 UTC

Correlated Moves
Macro Event
News

U.S. CPI showed a month-over-month decrease, boosting demand for Treasury bonds. The iShares 20+ Year Treasury Bond ETF remains higher than Monday's close.

14 jul 2026, 19:37 UTC

News
Social Media

KeyBanc maintains Overweight rating on Intel, raising price target to $155. Strong demand for AI-driven CPUs and improved yields support upward movement in shares today.

Peer Vergelijking

Prijswijziging

Iovance Biotherapeutics Inc Prognose

Koersdoel

By TipRanks

142.57% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 9.8 USD  142.57%

Hoogste 14 USD

Laagste 5 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Iovance Biotherapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Sentiment

By Acuity

68 / 342 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
help-icon Live chat